CTMX CytomX Therapeutics, Inc.
Nasdaq · SEC CIK 1501989 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $1.69M 6 sales by 4 insiders
- Filings on record
- 135 since 2021-08-13, latest 2026-08-05 19:33
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| McCarthy Sean A. | CEO, Dir | — | $1.23M |
| BELVIN MARCIA | SVP, CSO | — | $202.2K |
| Chu Yu-Waye | Chief Medical Off | — | $136.6K |
| Ogden Christopher | CFO | — | $129.0K |
| Lester Rachael | Chief Business Off | — | — |
| Carvajal Alejandra | CLO | — | — |
Transactions 101
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-05 19:33 | 2026-08-03 | CTMX | Carvajal Alejandra | CLO | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
| 2026-06-17 18:38 | 2026-06-15 | CTMX | Ogden Christopher | CFO | S - Sale | $3.05 | -1,624 | 295.3K | -0.5% | -$4,953 | |
| 2026-03-19 | 2026-03-17 | CTMX | Chu Yu-Waye | Chief Medical Off | S - Sale | $6.42 | -21.3K | 189.4K | -10% | -$136.6K | |
| 2026-03-19 | 2026-03-17 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale | $6.42 | -31.5K | 300.8K | -9% | -$202.2K | |
| T | 2026-03-19 | 2026-03-17 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $6.42 | -119.0K | 1.08M | -10% | -$763.8K |
| 2026-03-19 | 2026-03-17 | CTMX | Ogden Christopher | CFO | S - Sale | $6.42 | -19.3K | 296.9K | -6% | -$124.1K | |
| D | 2026-02-04 | 2026-02-02 | CTMX | Lester Rachael | Chief Business Off | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| D | 2026-02-04 | 2026-02-02 | CTMX | Ogden Christopher | CFO | A - Grant | $0.00 | +90.0K | 316.3K | +40% | $0 |
| D | 2026-02-04 | 2026-02-02 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +60.0K | 332.3K | +22% | $0 |
| D | 2026-02-04 | 2026-02-02 | CTMX | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +75.0K | 210.7K | +55% | $0 |
| D | 2026-02-04 | 2026-02-02 | CTMX | McCarthy Sean A. | CEO, Dir | A - Grant | $0.00 | +210.0K | 1.20M | +21% | $0 |
| T | 2025-11-10 | 2025-11-06 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $4.54 | -101.8K | 987.9K | -9% | -$462.1K |
| D | 2025-06-17 | 2025-06-16 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale+OE | $2.69 | -55.5K | 1.09M | -5% | -$149.3K |
| D | 2025-06-17 | 2025-06-13 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $0.00 | +150.0K | 1.15M | +15% | $0 |
| D | 2025-06-17 | 2025-06-13 | CTMX | Ogden Christopher | CFO | M - OptEx | $0.00 | +37.5K | 236.9K | +19% | $0 |
| DM | 2025-06-17 | 2025-06-13+ | CTMX | Ogden Christopher | CFO | S - Sale+OE | $2.72 | -12.3K | 199.4K | -6% | -$33.4K |
| D | 2025-06-17 | 2025-06-13 | CTMX | BELVIN MARCIA | SVP, CSO | M - OptEx | $0.00 | +37.5K | 286.1K | +15% | $0 |
| D | 2025-06-17 | 2025-06-16 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale+OE | $2.69 | -13.9K | 272.3K | -5% | -$37.3K |
| 2025-03-20 | 2025-03-18 | CTMX | ROWLAND LLOYD A | GC | S - Sale | $0.6 | -10.2K | 120.6K | -8% | -$6,122 | |
| 2025-03-20 | 2025-03-18 | CTMX | Chu Yu-Waye | Chief Medical Off | S - Sale | $0.6 | -4,025 | 135.7K | -3% | -$2,415 | |
| 2025-03-20 | 2025-03-18 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $0.6 | -37.7K | 995.2K | -4% | -$22.6K | |
| 2025-03-20 | 2025-03-18 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale | $0.6 | -19.5K | 248.6K | -7% | -$11.7K | |
| 2025-03-20 | 2025-03-18 | CTMX | Ogden Christopher | CFO | S - Sale | $0.6 | -8,551 | 201.0K | -4% | -$5,131 | |
| DMA | 2025-02-10 | 2025-02-04 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +92.5K | 210.6K | +78% | $0 |
| DM | 2025-02-06 | 2025-02-04 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +87.5K | 263.1K | +50% | $0 |
| DM | 2025-02-06 | 2025-02-04 | CTMX | Ogden Christopher | CFO | A - Grant | $0.00 | +101.5K | 209.6K | +94% | $0 |
| DM | 2025-02-06 | 2025-02-04 | CTMX | McCarthy Sean A. | CEO, Dir | A - Grant | $0.00 | +375.0K | 837.9K | +81% | $0 |
| DM | 2025-02-06 | 2025-02-04 | CTMX | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +113.5K | 82.2K | New | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | ROWLAND LLOYD A | GC | M - OptEx | $0.00 | +11.2K | 135.0K | +9% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | ROWLAND LLOYD A | GC | S - Sale+OE | $1.23 | -4,181 | 130.8K | -3% | -$5,143 |
| D | 2024-08-22 | 2024-08-20 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale+OE | $1.23 | -13.9K | 657.9K | -2% | -$17.1K |
| D | 2024-08-22 | 2024-08-20 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $0.00 | +37.5K | 671.7K | +6% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | BELVIN MARCIA | SVP, CSO | M - OptEx | $0.00 | +11.2K | 179.8K | +7% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale+OE | $1.23 | -4,181 | 175.6K | -2% | -$5,143 |
| D | 2024-08-22 | 2024-08-20 | CTMX | Landau Jeffrey B | Chief Business Off | M - OptEx | $0.00 | +11.2K | 123.2K | +10% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | Landau Jeffrey B | Chief Business Off | S - Sale+OE | $1.23 | -4,181 | 119.1K | -3% | -$5,143 |
| D | 2024-08-22 | 2024-08-20 | CTMX | Ogden Christopher | CFO | M - OptEx | $0.00 | +6,875 | 110.1K | +7% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | Ogden Christopher | CFO | S - Sale+OE | $1.23 | -1,984 | 108.1K | -2% | -$2,440 |
| D | 2024-06-14 | 2024-06-12 | CTMX | Ogden Christopher | CFO | A - Grant | $0.00 | +17.5K | 103.2K | +20% | $0 |
| D | 2024-03-28 | 2024-03-26 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $1.57 | +109.8K | 634.2K | +21% | +$172.3K |
| 2024-03-21 | 2024-03-19 | CTMX | Landau Jeffrey B | Chief Business Off | S - Sale | $2.09 | -6,562 | 110.1K | -6% | -$13.7K | |
| 2024-03-21 | 2024-03-19 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale | $2.09 | -12.8K | 168.6K | -7% | -$26.7K | |
| 2024-03-21 | 2024-03-19 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $2.09 | -20.2K | 524.5K | -4% | -$42.3K | |
| 2024-03-21 | 2024-03-19 | CTMX | ROWLAND LLOYD A | GC | S - Sale | $2.09 | -5,268 | 117.7K | -4% | -$11.0K | |
| 2024-03-21 | 2024-03-19 | CTMX | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $2.09 | -2,971 | 85.7K | -3% | -$6,209 | |
| D | 2024-01-19 | 2024-01-18 | CTMX | ROWLAND LLOYD A | GC | A - Grant | $0.00 | +25.0K | 123.0K | +26% | $0 |
| D | 2024-01-19 | 2024-01-18 | CTMX | Ogden Christopher | SVP, Fin, Accounting | A - Grant | $0.00 | +40.0K | 88.7K | +82% | $0 |
| D | 2024-01-19 | 2024-01-18 | CTMX | Landau Jeffrey B | Chief Business Off | A - Grant | $0.00 | +30.0K | 116.6K | +35% | $0 |
| D | 2024-01-19 | 2024-01-18 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +26.2K | 181.4K | +17% | $0 |
| D | 2024-01-19 | 2024-01-18 | CTMX | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +26.2K | 26.2K | New | $0 |
| D | 2024-01-19 | 2024-01-18 | CTMX | McCarthy Sean A. | CEO, Dir | A - Grant | $0.00 | +90.0K | 544.7K | +20% | $0 |
| 2023-12-22 | 2023-12-20 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale | $1.38 | -4,077 | 155.1K | -3% | -$5,626 | |
| 2023-12-22 | 2023-12-20 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $1.38 | -13.6K | 454.7K | -3% | -$18.7K | |
| 2023-12-22 | 2023-12-20 | CTMX | ROWLAND LLOYD A | GC | S - Sale | $1.38 | -4,077 | 98.0K | -4% | -$5,626 | |
| 2023-12-22 | 2023-12-20 | CTMX | Landau Jeffrey B | Chief Business Off | S - Sale | $1.38 | -4,077 | 86.6K | -4% | -$5,626 | |
| 2023-12-22 | 2023-12-20 | CTMX | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $1.38 | -1,990 | 48.7K | -4% | -$2,746 | |
| D | 2023-12-19 | 2023-12-17 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $0.00 | +37.5K | 468.3K | +9% | $0 |
| D | 2023-12-19 | 2023-12-17 | CTMX | BELVIN MARCIA | SVP, CSO | M - OptEx | $0.00 | +11.2K | 159.2K | +8% | $0 |
| D | 2023-12-19 | 2023-12-17 | CTMX | Ogden Christopher | SVP, Fin, Accounting | M - OptEx | $0.00 | +6,875 | 50.6K | +16% | $0 |
| D | 2023-12-19 | 2023-12-17 | CTMX | Landau Jeffrey B | Chief Business Off | M - OptEx | $0.00 | +11.2K | 90.7K | +14% | $0 |
| D | 2023-12-19 | 2023-12-17 | CTMX | ROWLAND LLOYD A | GC | M - OptEx | $0.00 | +11.2K | 102.1K | +12% | $0 |
| 2023-09-22 | 2023-09-22 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale | $1.30 | -4,119 | 148.0K | -3% | -$5,355 | |
| 2023-09-22 | 2023-09-20 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +11.2K | 152.1K | +8% | $0 | |
| 2023-09-22 | 2023-09-20 | CTMX | McCarthy Sean A. | CEO, Dir | A - Grant | $0.00 | +40.0K | 445.4K | +10% | $0 | |
| 2023-09-22 | 2023-09-22 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $1.30 | -14.6K | 430.8K | -3% | -$19.0K | |
| 2023-09-22 | 2023-09-20 | CTMX | Landau Jeffrey B | Chief Business Off | A - Grant | $0.00 | +11.2K | 80.5K | +16% | $0 | |
| 2023-09-22 | 2023-09-22 | CTMX | Landau Jeffrey B | Chief Business Off | S - Sale | $1.30 | -4,119 | 76.4K | -5% | -$5,355 | |
| 2023-09-22 | 2023-09-22 | CTMX | ROWLAND LLOYD A | GC | S - Sale | $1.30 | -5,486 | 80.6K | -6% | -$7,132 | |
| 2023-09-22 | 2023-09-20 | CTMX | ROWLAND LLOYD A | GC | A - Grant | $0.00 | +15.0K | 86.1K | +21% | $0 | |
| D | 2023-05-23 | 2023-05-19 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $1.57 | +16.5K | 405.4K | +4% | +$26.0K |
| 2023-03-31 | 2023-03-29 | CTMX | Jones Elaine V | Dir | P - Purchase | $1.55 | +5,000 | 5,142 | +3,521% | +$7,750 | |
| 2023-03-29 | 2023-03-22 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +60.0K | 140.8K | +74% | $0 | |
| 2023-03-20 | 2023-03-16 | CTMX | Landau Jeffrey B | CFO | S - Sale | $1.98 | -1,477 | 69.2K | -2% | -$2,924 | |
| 2023-03-20 | 2023-03-16 | CTMX | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $1.98 | -516 | 37.8K | -1% | -$1,022 | |
| 2023-03-20 | 2023-03-16 | CTMX | Campoy Carlos | CFO | S - Sale | $1.98 | -1,748 | 38.2K | -4% | -$3,461 | |
| 2023-03-20 | 2023-03-16 | CTMX | ROWLAND LLOYD A | GC | S - Sale | $1.98 | -2,037 | 71.1K | -3% | -$4,033 | |
| 2023-03-20 | 2023-03-16 | CTMX | Peterson Amy C. | EVP, Chief Development Off | S - Sale | $1.98 | -4,257 | 58.4K | -7% | -$8,429 | |
| 2023-03-20 | 2023-03-16 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $1.88 | -7,121 | 388.8K | -2% | -$13.4K | |
| D | 2023-02-06 | 2023-02-02 | CTMX | ROWLAND LLOYD A | GC | A - Grant | $0.00 | +25.0K | 73.1K | +52% | $0 |
| D | 2023-02-06 | 2023-02-02 | CTMX | McCarthy Sean A. | CEO, Dir | A - Grant | $0.00 | +105.0K | 395.9K | +36% | $0 |
| D | 2023-02-06 | 2023-02-02 | CTMX | Ogden Christopher | SVP, Fin, Accounting | A - Grant | $0.00 | +25.0K | 38.3K | +188% | $0 |
| D | 2023-02-06 | 2023-02-02 | CTMX | Landau Jeffrey B | Chief Business Off | A - Grant | $0.00 | +40.0K | 70.7K | +130% | $0 |
| 2022-07-21 | 2022-07-19 | CTMX | Campoy Carlos | CFO | A - Grant | $0.00 | +15.0K | 43.9K | +52% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | Campoy Carlos | CFO | S - Sale | $1.42 | -3,949 | 40.0K | -9% | -$5,608 | |
| 2022-07-21 | 2022-07-19 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | A - Grant | $0.00 | +40.0K | 305.9K | +15% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | S - Sale | $1.42 | -14.9K | 290.9K | -5% | -$21.2K | |
| 2022-07-21 | 2022-07-19 | CTMX | HANNAH ALISON L. | Chief Medical Off | A - Grant | $0.00 | +15.0K | 37.5K | +67% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | HANNAH ALISON L. | Chief Medical Off | S - Sale | $1.42 | -5,602 | 31.9K | -15% | -$7,955 | |
| 2022-07-21 | 2022-07-19 | CTMX | Peterson Amy C. | EVP, Chief Development Off | A - Grant | $0.00 | +20.0K | 70.2K | +40% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | Peterson Amy C. | EVP, Chief Development Off | S - Sale | $1.42 | -7,463 | 62.7K | -11% | -$10.6K | |
| 2022-07-21 | 2022-07-19 | CTMX | ROWLAND LLOYD A | GC | A - Grant | $0.00 | +15.0K | 49.3K | +44% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | ROWLAND LLOYD A | GC | S - Sale | $1.42 | -5,602 | 43.7K | -11% | -$7,955 | |
| 2022-07-21 | 2022-07-19 | CTMX | Landau Jeffrey B | Chief Business Off | A - Grant | $0.00 | +11.2K | 34.9K | +48% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | Landau Jeffrey B | Chief Business Off | S - Sale | $1.42 | -4,206 | 30.7K | -12% | -$5,973 | |
| DM | 2022-05-11 | 2022-05-09 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | M - OptEx | $0.95 | +90.9K | 241.7K | +60% | +$86.4K |
| D | 2022-02-04 | 2022-02-02 | CTMX | Peterson Amy C. | EVP, Chief Development Off | A - Grant | $0.00 | +40.0K | 46.4K | +623% | $0 |
| D | 2022-02-04 | 2022-02-02 | CTMX | HANNAH ALISON L. | Chief Medical Off | A - Grant | $0.00 | +22.5K | 22.5K | New | $0 |
| D | 2022-02-04 | 2022-02-02 | CTMX | Campoy Carlos | CFO | A - Grant | $0.00 | +22.5K | 28.9K | +350% | $0 |
| D | 2022-02-04 | 2022-02-02 | CTMX | ROWLAND LLOYD A | GC | A - Grant | $0.00 | +22.5K | 34.3K | +191% | $0 |
| D | 2022-02-04 | 2022-02-02 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | A - Grant | $0.00 | +75.0K | 174.9K | +75% | $0 |
Purchase Sale Sale after option exercise All abbreviations